Cited by Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy DOI

Muhua Chen,

Lei Bie,

Ying Jieer

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 167, P. 115514 - 115514

Published: Sept. 15, 2023

Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and constitutively expressed on surface of immune cells. As a receptor checkpoint, PD-1 can bind to programmed ligand-1/programmed ligand-2 (PD-L1/PD-L2) in tumor cells, leading evasion. Anti-PD-1 anti-PD-L1 are important components therapy. as an intrinsic variant (iPD-1) cancer cells where it plays roles malignant progression proposed recent studies. However, iPD-1 has received much less attention compared although there unmet medical need for fully elucidating mechanisms actions achieve best response immunotherapy. suppresses tumorigenesis non-small lung (NSCLC) colon cancer, whereas promotes melanoma, hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), thyroid (TC), glioblastoma (GBM), triple-negative breast (TNBC). In this review, we focus role development its molecular mechanisms. We deeply discuss nivolumab-based combined therapy common may explain different therapeutic effects anti-PD-1 treatment provide critical information use anti-tumor approaches.

Language: Английский

Citations

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy DOI

Tao Lei, Yazhuo Wang, Yuchen Zhang

et al.

Leukemia, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 25, 2024

Language: Английский

Citations

The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications DOI

Yu Ma, Ting Wang, Xudong Zhang

et al.

Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(5)

Published: May 2, 2024

Abstract Cancer immunotherapy has rapidly transformed cancer treatment, yet resistance remains a significant hurdle, limiting its efficacy in many patients. Circular RNAs (circRNAs), novel class of non-coding RNAs, have emerged as pivotal regulators gene expression and cellular processes. Increasing evidence indicates their involvement modulating to immunotherapy. Notably, certain circRNAs function miRNA sponges or interact with proteins, influencing the immune-related genes, including crucial immune checkpoint molecules. This, turn, shapes tumor microenvironment significantly impacts response In this comprehensive review, we explore evolving role orchestrating immunotherapy, specific focus on mechanisms expression. Additionally, underscore potential promising therapeutic targets augment effectiveness Understanding could contribute development new strategies overcome improve patient outcomes.

Language: Английский

Citations

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers DOI

Maishara Muquith, Magdalena Espinoza, Andrew Elliott

et al.

Nature Cancer, Journal Year: 2024, Volume and Issue: 5(7), P. 1121 - 1129

Published: March 25, 2024

Language: Английский

Citations

Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors DOI

G. Sivaiah,

M.S. Raghu, S. Prasad

et al.

Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: 1309, P. 138223 - 138223

Published: April 3, 2024

Language: Английский

Citations